Healthcare Network and User Base - As of June 30, 2025, the platform has connected over 44,800 healthcare institutions, including more than 14,500 hospitals and over 30,300 grassroots healthcare institutions[10]. - The registered individual users on the platform reached 56.9 million, with an average of 3.3 million monthly active users in the six months ending June 30, 2025[10]. - The company collaborates with over 904,500 healthcare professionals, including approximately 46,700 registered doctors, to enrich its medical resources[10]. - The company has developed a digital healthcare service platform that integrates online and offline healthcare services, significantly expanding its service reach to over 260 cities nationwide[10]. - The company has established 11 regional operation centers in key areas such as Shenzhen, Beijing, Shanghai, and Guangzhou to enhance local service coverage[11]. Financial Performance - Total revenue for the six months ended June 30, 2025, was RMB 290.7 million, representing a year-on-year increase of 6.2%[16]. - Revenue from pharmaceutical health products sales reached RMB 211.4 million, up 7.4% year-on-year[19]. - The company reported an operating loss of RMB 18.0 million, a significant improvement of 77.8% compared to the previous year's loss of RMB 81.2 million[16]. - The adjusted net loss (non-IFRS measure) was RMB 5.1 million, a reduction of 83.7% from RMB 31.0 million in the prior year[16]. - Revenue from digital healthcare solutions was RMB 79.3 million, reflecting a year-on-year growth of 2.9%[20]. Cost Management and Expenses - Sales and marketing expenses decreased by 45.5% from approximately RMB 64.9 million to approximately RMB 35.4 million, primarily due to reduced employee benefits expenses and improved cost control measures[32]. - Administrative expenses fell by 46.5% from approximately RMB 51.5 million to approximately RMB 27.5 million, mainly due to a reduction in share-based payment expenses and travel costs[33]. - Research and development expenses decreased by 30.5% from approximately RMB 25.1 million to approximately RMB 17.5 million, reflecting a reduction in employee benefits expenses[35]. - The gross margin for pharmaceutical health products sales decreased from 1.9% to 1.3%, while the retail model's gross margin increased from 13.1% to 16.2% due to strategic adjustments in product selection and promotional activities[31]. Cash Flow and Liquidity - The operating cash flow for the six months ended June 30, 2025, was a net outflow of RMB 5.4 million, an improvement from a net outflow of RMB 40.7 million in the same period of 2024[44]. - The company reported a net cash inflow from financing activities of RMB 12.3 million for the six months ended June 30, 2025, compared to RMB 36.7 million in the same period of 2024[44]. - As of June 30, 2025, the company's cash and cash equivalents amounted to approximately RMB 66.8 million, an increase from RMB 58.3 million as of December 31, 2024[43]. - The company’s total liabilities exceeded current assets by RMB 107,091,000 as of June 30, 2025, highlighting potential liquidity challenges[111]. Shareholder and Equity Information - The total number of issued shares is 336,452,810[68]. - Major shareholders include Mr. Luo, holding approximately 30.59% of the company's shares[73]. - The company approved a pre-IPO share option plan on August 31, 2023, aimed at attracting and retaining senior management and employees[79]. - A total of 14,487,990 new shares and 16,696,595 existing shares can be issued under the pre-IPO share option plan, representing 4.31% and 4.96% of the total issued shares post-split and global offering, respectively[81]. - The company aims to align the interests of option holders with those of shareholders through the share option plan[79]. Future Plans and Investments - The company plans to adopt new accounting standards effective January 1, 2026, but does not expect significant impacts on its financial position or performance[113]. - The company plans to list its shares on the Hong Kong Stock Exchange on September 17, 2025[162]. - The company has no specific future plans for significant investments or capital assets as of June 30, 2025[50]. - The company continues to expand its market presence and promote its digital hospital solutions to enhance service levels and reach more regions[18]. Guarantees and Related Party Transactions - The company provided a revolving credit loan of RMB 60 million to its controlling shareholder, Mr. Luo, with an interest rate between 3.45% and 6%[151]. - The company has guaranteed loans totaling RMB 28,000,000 as of June 30, 2025, with various related parties providing collateral[152]. - The company has a loan guarantee of RMB 5,000,000 from Bank H, guaranteed by Mr. Luo, with a start date of January 13, 2025, and an end date of January 12, 2026[154].

Core Viewpoint - Health 160 (02656) announced the appointment of Ms. Sun Meng as a non-executive director and Mr. Zou Jun as an independent non-executive director to the nomination committee of the board, effective from September 29, 2025 [1] Group 1 - Ms. Sun Meng has been appointed as a member of the nomination committee [1] - Mr. Zou Jun has also been appointed as a member of the nomination committee [1] - The appointments will take effect on September 29, 2025 [1]

Core Viewpoint - Health 160 (02656) announced the appointment of non-executive director Sun Meng and independent non-executive director Zou Jun as members of the nomination committee under the board, effective from September 29, 2025 [1] Group 1 - The appointment of Sun Meng and Zou Jun is aimed at enhancing the governance structure of the company [1]

執行董事 羅寧政先生 （董事長） 冀翠琳先生 黃浪先生 王立法先生 160 Health International Limited 健 康 160 国际有限公司 （於開曼群島註冊成立之有限公司） 董事名單與其角色和職能 健康160国际有限公司董事（「董事」）會（「董事會」）成員載列如下： | 委員會 | 審核委員會 | 薪酬委員會 | 提名委員會 | | --- | --- | --- | --- | | 董事 | | | | | 羅寧政先生 | – | 成員 | 主席 | | 冀翠琳先生 | – | – | – | | 黃浪先生 | – | – | – | | 王立法先生 | – | – | – | | 張如協先生 | 成員 | – | – | | 孫萌女士 | – | – | 成員 | | 鄒鈞先生 | 主席 | 成員 | 成員 | | 徐衛國博士 | 成員 | 主席 | 成員 | | 范明博士 | – | – | 成員 | 中國深圳，2025年9月29日 非執行董事 張如協先生 孫萌女士 獨立非執行董事 鄒鈞先生 徐衛國博士 范明博士 董事會已設立三個委員會。各董事委員會的成員載列如下： ...

健康160国际有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，非執行 董事孫萌女士及獨立非執行董事鄒鈞先生已獲委任為董事會轄下提名委員會（「提 名委員會」）成員，自2025年9月29日起生效。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 160 Health International Limited 健 康 160 国际有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2656） 委任提名委員會成員 董事長、執行董事兼首席執行官 上述委任後，提名委員會由五名成員組成，即羅寧政先生（主席）、孫萌女士、鄒 鈞先生、徐衛國博士及范明博士。 於本公告日期，董事會包括：(i)執行董事羅寧政先生、冀翠琳先生、黃浪先生及 王立法先生；(ii)非執行董事張如協先生及孫萌女士；及(iii)獨立非執行董事鄒鈞 先生、徐衛國博士及范明博士。 承董事會命 健康160国际有限公司 羅寧政先生 香港，2025年9月29日 ...

160 Health International Limited 健 康 160 国际有限公司 Arrangement of Electronic Dissemination of Corporate Communications Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, 160 Health International Limited (the "Company") is writing to inform you that the Company has adopted electron ...

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, 160 Health International Limited (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to ...

Summary of Key Points Core Viewpoint The article discusses the recent activities on the Hong Kong Stock Exchange (HKEX) from September 15 to September 21, highlighting the number of companies that submitted applications, those that passed hearings, and new listings. Group 1: Companies Submitting Applications - A total of 11 companies submitted applications to the HKEX during the specified period [1] - Notable companies include: - **Meilian Steel Structure (Shanghai) Co., Ltd.**: Ranked third in China's prefabricated steel structure market with a market share of 3.5% [2] - **Hangzhou New Element Pharmaceutical Co., Ltd.**: Focused on developing therapies for metabolic, inflammatory, and cardiovascular diseases [3] - **Jiangsu Zhongrun Solar Technology Co., Ltd.**: Second in global photovoltaic cell manufacturing with a market share of 14.6% [4] - **Beijing Junzheng Integrated Circuit Co., Ltd.**: A leading provider of chips for various high-tech applications [5] - **Shanghai Aike Baifa Biopharmaceutical Technology Co., Ltd.**: Focused on therapies for respiratory and pediatric diseases [7] - **Nuwa Insight Technology Co., Ltd.**: An AI technology company in the insurance sector [8] - **Huaqin Technology Co., Ltd.**: A leading ODM platform for smart products [9] - **Saimite Information Group Co., Ltd.**: A leading provider of intelligent industrial software solutions [10] - **Guangzhou Ruoyu Chen Technology Co., Ltd.**: An e-commerce operation company [11] - **Quantitative Holdings Limited**: Focused on online market operations in the consumer sector [12] - **Hangzhou Xianweida Biotechnology Co., Ltd.**: A biopharmaceutical company nearing commercialization [13] Group 2: Companies Passing Hearings - Two companies successfully passed the listing hearings: - **Shenzhen Xipuni Precision Technology Co., Ltd.**: A designer and manufacturer of gold watch cases and bands [14] - **Xuanzhu Biotechnology Co., Ltd.**: An innovative biopharmaceutical company with multiple drug assets in development [15] Group 3: Companies Launching IPOs - Four companies initiated their IPOs: - **Jingfang Pharmaceutical-B**: Global offering of 89.24 million shares with a net fundraising of approximately HKD 1.67 billion [17] - **Different Group**: Global offering of 10.98 million shares with a price range of HKD 62.01-71.20 [18] - **Chery Automobile**: Global offering of 297 million shares with a price range of HKD 27.75-30.75 [19] - **Zijin Gold International**: Global offering of 349 million shares with a price of HKD 71.59 [20] Group 4: New Listings - Three new stocks were listed: - **Hesai Technology (HK:02525)**: Closed at HKD 234.0 per share, up 9.96% on the first day [20] - **Health 160 (HK:02656)**: Closed at HKD 28.22 per share, up 137.34% on the first day [21] - **Jingfang Pharmaceutical-B (HK:02595)**: Closed at HKD 42.10 per share, up 106.47% on the first day [22]

Group 1: IPO Market Activity - The Hong Kong IPO market has seen a surge in diverse companies, including leaders in digital healthcare and lidar technology, with significant activity from sectors like prefabricated steel structures and photovoltaic cells [2][3] - Health160, China's largest digital healthcare service platform, saw its stock price soar by 137.34% on its debut, covering over 260 cities and connecting 44,600 medical institutions [6] - Hesai Technology, a leader in the lidar sector, achieved a dual listing on both US and Hong Kong exchanges, with a market capitalization exceeding HKD 36 billion on its first day [7][8] Group 2: Companies Approved for IPO - Yuan Chuang Technology has received approval for its mainboard IPO, focusing on the research, production, and sales of rubber tracks for agricultural and engineering machinery, with projected revenues of CNY 1.261 billion in 2022 [4] - New Guangyi, a high-tech enterprise specializing in high-performance functional materials, also received approval for its IPO, with revenues expected to grow from CNY 455 million in 2022 to CNY 657 million in 2024 [5] Group 3: New Listings - Jinfang Pharmaceutical made its debut on the Hong Kong Stock Exchange, with an opening surge of 115.79%, focusing on innovative therapies for tumors and autoimmune diseases [9] - Meilian Steel Structure, a prefabricated steel structure service provider, has refiled for an IPO, reporting a revenue increase of 180% year-on-year for the first half of 2025 [10][11] Group 4: Upcoming IPOs - Zijin Gold International plans to raise approximately USD 3.2 billion through its IPO, potentially becoming the largest IPO since May, coinciding with record-high gold prices [17][18] - Huakin Technology, a leading smart product platform, has submitted its IPO application, reporting a revenue increase of 113.06% year-on-year for the first half of 2025 [12]

Core Viewpoint - Health 160 (02656.HK) announced that it will hold a board meeting on September 29, 2025, to approve the interim report for the six months ending June 30, 2025 [1] Group 1 - The board meeting is scheduled for September 29, 2025 [1] - The purpose of the meeting is to approve the group's interim report [1] - The interim report will cover the six months ending June 30, 2025 [1]